"The future of life sciences is determined by the choices we make today. Our survey showed that life sciences companies are both taking risks to foster scientific advancement and building more resilience and safety into their businesses and networks. The result? We’re going to see leaps in the life sciences industry leading to better products for patients and a brighter future for the world."
LANCE MINOR
Principal and National Co-Leader, BDO Life Sciences, BioProcess Technology Group
2022 BDO Life Sciences CDO Outlook Survey
By now, it’s clear: the alterations COVID-19 made to the life sciences landscape aren’t going away.
Fortunately, some of those changes are largely positive: developments made during the pandemic have given rise to new investment opportunities and advanced drug development techniques.
Now, the industry is facing a new world: one where partnerships are preferred, technology is the ticket to de-risking drug development, and supply chain disruptions could threaten the very lifeblood of life sciences.
The 2022 BDO Life Sciences CFO Outlook Survey polls life sciences industry CFOs to understand their plans to navigate this new world — and how they will shape the future of the industry.
Dive into the survey findings to explore the challenges and opportunities facing life sciences in 2022
Methodology
The 2022 BDO Life Sciences CFO Outlook Survey polled 100 life sciences industry CFOs with revenues ranging from $100 million to $3 billion in October 2021. The survey was conducted by Rabin Research Company, an independent marketing research firm, using Op4G’s panel of executives.
Annual Revenue
9% $2B-$3B+
18% $1B-$2B
14% $751M-$999M
13% $501M-$700M
8% $251M-$500M
38% $100M-$250M
Regional Operations For U.S.-Based Companies
63% U.S. only
28% Canada
22% Europe
21% Latin/South America
19% Asia-Pacific
4% Africa
Ownership
50% Private
50% Public
Types of Life Sciences Organization
20% Biopharma / Pharma
20% Biotech
20% Medtech
20% Medical devices
20% Drug manufacturers / supplies
SHARE